Combined Limited Use License and Statement of Use

Combined Limited Use License and Statement of Use
Document 14-22 REF V-05

bit.bio
The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge CB22 3FH
United Kingdom
www.bit.bio



Combined Limited Use License and Statement of Use

BEFORE PLACING AN ORDER OR USING THIS PRODUCT, PLEASE READ THE TERMS AND CONDITIONS SET FORTH BELOW. BY USE OF THE PRODUCT, USER AGREES TO BE BOUND BY THE TERMS OF THIS COMBINED LIMITED USE LICENSE AND STATEMENT OF USE AND THE STANDARD TERMS AND CONDITIONS OF SALE V-02 OR E-COMMERCE TERMS AND CONDITIONS OF SALE V-01.

This Product is provided by Bit Bio Ltd. under licensing rights from licensors including Cambridge Enterprise Limited, iPS Academia Japan, Inc., TET Systems GmbH & Co., ID Pharma Co. Ltd., and ERS Genomics Limited. Use is limited as per the individual Limited Use License Notices or other license grant restrictions from each of the licensors. To the best of our knowledge no additional licenses are required by the User other than the Single Use TET license.

Definitions:

- Commercial Use: any and all uses of the Product, Progeny, Modifications or Unmodified Derivatives thereof, by a party for monetary or other consideration and may include but is not limited to use in:
 - I. Manufacture of a product;
 - II. Sale of a product, Progeny, Modifications or Unmodified Derivatives thereof, whether or not such sale is limited for use in research;
 - III. Provision of a service to a third party*;
 - IV. Use in any diagnostic, preventative, or therapeutic application;
 - V. Use in any veterinary, livestock or agricultural application; and
 - VI. Use in later stage development of therapeutics, diagnostics, prophylactics (e.g., hit-to-lead, lead optimization).
- 2. Field: use of the Product for User's internal research use only. No "Commercial Use" is allowed.
- 3. Modification(s): any modifications of the Product.
- 4. Product: Cells which are differentiated from human induced pluripotent stem cells by or on behalf of Bit Bio Ltd., and which Bit Bio Ltd. sells, or are sold on behalf of Bit Bio Ltd. by a distributor.
- 5. Progeny: any unmodified descendant form of the Product.
- 6. Unmodified Derivatives: any substances created by the User which constitute an unmodified functional subunit or product expressed by the Product.
- 7. User: Person or entity who purchased Product(s) from Bit Bio Ltd. or a distributor.

Combined Limited Use License and Statement of Use
Document 14-22 REF V-05

bit.bio
The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge CB22 3FH
United Kingdom
www.bit.bio

^{*} For services to a third party please contact Bit Bio Limited.

Ethical considerations and donor protection:

The specimens used to generate the parental human induced pluripotent stem cell (hiPSC) lines used by Bit Bio Ltd. to generate the Product(s) were collected with the informed consent of both the collection site and the individual donor(s), under good clinical practice, and in accord with all applicable law. Any personally identifiable health information collected from the donor(s) during specimen collection was anonymized consistent with the provisions of the Health Insurance Portability and Accessibility Act (HIPAA) and/or the General Data Protection Regulation, as applicable, and in any case, has not been shared with Bit Bio Ltd.

Usage terms specifically applicable to ioMicroglia™:

By taking delivery of the ioMicroglia[™] Product, the User agrees that:

- The User shall not make any attempt to identify the original donors
 of the Product(s) including by using Y-chromosome sequencing
 data. The User shall remove any data mapping to the Y
 chromosome (including sequencing reads, genotypes etc.) before
 making genetic or genomic data available to third parties, and such
 data shall be removed from publications or results; and
- In any publication in respect of the ioMicroglia[™] Product, the User shall record the role of Genome Research Limited in developing and providing the parental cell line, with an appropriate acknowledgement in accordance with academic custom.

Usage terms applicable to all Products:

All Product(s) manufactured by or on behalf of Bit Bio Ltd. are produced according to strict aseptic bio-banking procedures. Each manufactured cell lot is tested for sterility and absence of mycoplasma infection, both at the cryopreservation and post-thawing stages, as well as for the presence of certain common pathogens (i.e., hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus-1 (HIV-1), human immunodeficiency virus-2 (HIV-2)). As a precaution, all Bit Bio Ltd. cell Products should be handled under biosafety level 1 (BSL1) containment at a minimum, as with all cells derived from human or other primate material.

By taking delivery of the Product(s), the User agrees:

- The Product(s) will not be used in human subjects, administered to human subjects in clinical trials, or administered for diagnostic purposes involving human subjects;
- The Product(s) will be used only in compliance with applicable laws and regulations, and in compliance with User's applicable policies on research involving human subjects;
- In the case of entities receiving funding from the United States
 federal government to conduct human stem cell research, the
 Product(s) will be used in compliance with all federal, state, and
 local laws and regulations and the NIH Guidelines on Human Stem
 Cell Research (available at http://stemcells.nih.gov/policy), each as
 applicable;

Combined Limited Use License and Statement of Use
Document 14-22 REF V-05

bit.bio
The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge CB22 3FH
United Kingdom
www.bit.bio

- The Product(s) will not be used in research in which they are introduced into blastocysts from non-human primates; and
- The Product(s) will not be used in research involving the breeding of animals where the introduction of the material may contribute to the germ line.

If you require more information, please Bit Bio Ltd. at info@bit.bio

Combined Limited Use License and Statement of Use Document 14-22 REF V-05

bit.bio
The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge CB22 3FH
United Kingdom
www.bit.bio

Cambridge Enterprise Limited

This Product is manufactured and sold by Bit Bio Ltd. based on a patent license from Cambridge Enterprise Limited. This Product is covered by one or more claims in pending patent applications including: U.S. Patent Application No. 16/463,829 and foreign counterparts thereof, including their divisions, continuations, extensions, substitutions, and those claiming priority therefrom or those claiming the same priorities therein. Use is limited to the Field defined above.

Combined Limited Use License and Statement of Use Document 14-22 REF V-05

bit.bio
The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge CB22 3FH
United Kingdom
www.bit.bio

iPS Academia Japan, Inc. and ID Pharma Co. Ltd.

This Product is manufactured and sold by Bit Bio Ltd. based on a patent license from iPS Academia Japan, Inc. This Product is covered by one or more claims of issued patents and pending patent applications, including: U.S. Patent Nos. 8,048,999, 8,058,065, 8,129,187 and 8,278,104 and foreign counterparts thereof, including their divisions, continuations, extensions, substitutions, and those claiming priority therefrom or those claiming the same priorities therein.

This Product is manufactured by Bit Bio Ltd. also using technology licensed from ID Pharma Co. Ltd. This Product is covered by one or more claims of issued patents and pending patent applications, including: U.S. Patent No. 9,127,256 and European Patent No. 1186667 and foreign counterparts thereof, including their divisions, continuations, extensions, substitutions, and those claiming priority therefrom or those claiming the same priorities therein.

The use of this Product is strictly limited to User's own internal research as described and restricted in the iPS Academia Japan and ID Pharma Co. Ltd. User Restrictions Notice below.

User Restrictions:

- 1. All Users may use the Product for internal research only including but not limited to screening potential drug compounds for efficacy and safety. No other right is granted to User whether expressly, by implication, by estoppel or otherwise. In particular, the purchase of the Product does not include nor carry any right or license to use, develop or otherwise exploit the Product commercially, and no rights are conveyed to User to use the Product for any other purpose other than specified in the Field.
- 2. User agrees to use the Product in compliance with all applicable statutes and regulations, but not to use the Product for any administration or application to humans. Moreover, User agrees not to use the Product in human subjects for human clinical use for therapeutic, diagnostic or prophylactic purposes, or in animals for veterinary use for therapeutic, diagnostic or prophylactic purposes, including but not limited to clinical applications, cell therapy, transplantation, and/or regenerative medicine without an appropriate license.
- 3. In the case that User transfers Product to a third party, User shall convey the User Restrictions set forth herein to such a third party.

Combined Limited Use License and Statement of Use
Document 14-22 REF V-05

bit.bio
The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge CB22 3FH
United Kingdom
www.bit.bio

TET Systems GmbH & Co. KG

This Product contains the Tetracycline controllable expression system (the "Tet Technology"). The Tet Technology IP portfolio is proprietary to TET Systems GmbH & Co. KG ("TET Systems") and comprises a series of patents including U.S. patents 8,383,364, 9,181,556, European Patents EP 1954811, 2352833 and corresponding patent claims outside these regions. The purchaser of the Product (User) is granted an automatic license to use the Tet Technology only for the intended use of the Product and excludes the right to transfer or sell the Product, the Tet Technology or its component parts to third parties. Users whose research using the Product is sponsored by for-profit organizations, which shall receive ownership to any data or results stemming from the sponsored research, shall need a license agreement from TET Systems in order to use this Product.

In accepting this license, all Users of the Product acknowledge that the Tet Technology is experimental in nature. TET Systems makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products.

Under the terms specified in TET Systems' Limited Use License all Users of this Product that do not have a license from TET Systems will be restricted to the purchase of less than ten (10) units per annum. In case the User is purchasing more than ten (10) units, a TET license will be required from TET Systems GmbH & Co. KG.

Please contact Bit Bio Limited for more information.

Combined Limited Use License and Statement of Use
Document 14-22 REF V-05

bit.bio
The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge CB22 3FH
United Kingdom
www.bit.bio

ERS GENOMICS Limited

CRISPR non-exclusive license agreement

This Product is manufactured and supplied by Bit Bio Limited using technology covered by one or more issued patents within and outside the UK claiming priority to one or more of US Provisional Patent Application Numbers 61/652,086, 61/716,256, 61/757,640, and 61/765,576 provided under license from ERS GENOMICS Limited. Certain commercial entities and/or activities performed at commercial entities may require additional contract rights from ERS Genomics Limited which are not granted through the purchase of this Product. For additional information please see www.ersgenomics.com/research-products.php.

The User (purchaser) receives a non-exclusive, non-transferable right to use the Product, Progeny, Modifications and Unmodified Derivatives thereof for RESEARCH USE ONLY, which, subject to the exclusions below, includes use to discover and develop any product, including therapeutic products, which may then be sold to third parties, provided, however, that such products do not incorporate the Product, Progeny, Modifications, or Unmodified Derivatives.

For clarity, transfer of materials or provision of services by not for profit or academic core laboratories to their internal clients shall not constitute a Commercial Use.

Except for the rights granted herein, any and all rights to the Product, Progeny, Modifications or Unmodified Derivatives thereof, shall remain in Bit Bio Ltd. No ownership rights are transferred.

The User shall have no right to assign the rights granted herein to third parties. The Product, Progeny, Modifications or Unmodified Derivatives thereof, must at all times remain in the possession of the User, except for a transfer to a scientific collaborator or to a service provider, to perform services, solely on behalf of the User.

ERS Genomics Limited is an intended third-party beneficiary under this Combined Limited Use License and Statement of Use.

Combined Limited Use License and Statement of Use
Document 14-22 REF V-05

bit.bio
The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge CB22 3FH
United Kingdom
www.bit.bio